The stock of Illumina, Inc. (NASDAQ:ILMN) is a huge mover today! About 1.70 million shares traded hands or 40.50% up from the average. Illumina, Inc. (NASDAQ:ILMN) has declined 9.16% since March 9, 2016 and is downtrending. It has underperformed by 16.57% the S&P500.
The move comes after 5 months positive chart setup for the $15.12B company. It was reported on Oct, 12 by Barchart.com. We have $197.47 PT which if reached, will make NASDAQ:ILMN worth $6.65B more.
Analysts await Illumina, Inc. (NASDAQ:ILMN) to report earnings on October, 18. They expect $0.91 EPS, up 13.75% or $0.11 from last year’s $0.8 per share. ILMN’s profit will be $100.34 million for 37.67 P/E if the $0.91 EPS becomes a reality. After $0.86 actual EPS reported by Illumina, Inc. for the previous quarter, Wall Street now forecasts 5.81% EPS growth.
Illumina, Inc. (NASDAQ:ILMN) Ratings Coverage
Out of 22 analysts covering Illumina Inc (NASDAQ:ILMN), 7 rate it a “Buy”, 1 “Sell”, while 14 “Hold”. This means 32% are positive. Illumina Inc has been the topic of 45 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Morgan Stanley maintained Illumina, Inc. (NASDAQ:ILMN) rating on Tuesday, April 19. Morgan Stanley has “Equal-Weight” rating and $140 price target. The stock has “Neutral” rating given by CL King on Monday, August 22. The rating was initiated by Argus Research with “Buy” on Wednesday, March 30. Citigroup downgraded Illumina, Inc. (NASDAQ:ILMN) on Tuesday, October 11 to “Neutral” rating. The firm has “Market Perform” rating given on Thursday, October 1 by Leerink Swann. Cantor Fitzgerald downgraded Illumina, Inc. (NASDAQ:ILMN) rating on Tuesday, April 19. Cantor Fitzgerald has “Hold” rating and $165 price target. Deutsche Bank initiated the shares of ILMN in a report on Thursday, January 7 with “Hold” rating. Stifel Nicolaus maintained the shares of ILMN in a report on Tuesday, October 6 with “Buy” rating. The company was maintained on Monday, December 21 by Stifel Nicolaus. The firm has “Neutral” rating given on Tuesday, October 6 by Mizuho.
According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”
Insitutional Activity: The institutional sentiment decreased to 1.1 in 2016 Q2. Its down 0.03, from 1.13 in 2016Q1. The ratio fall, as 66 funds sold all Illumina, Inc. shares owned while 150 reduced positions. 46 funds bought stakes while 191 increased positions. They now own 137.98 million shares or 3.82% less from 143.46 million shares in 2016Q1.
Glob X Mgmt Company Ltd Company last reported 0% of its portfolio in the stock. Aqr Capital Management Ltd Limited Liability Company holds 0% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 19,268 shares. Dowling Yahnke Lc holds 0.04% or 2,097 shares in its portfolio. Brave Asset Mngmt last reported 390 shares in the company. The Japan-based Diam has invested 0.06% in Illumina, Inc. (NASDAQ:ILMN). Arrowgrass Capital (Us) Limited Partnership accumulated 14,750 shares or 0.02% of the stock. Clearbridge Investments Ltd Liability Co holds 0% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 205 shares. Cornerstone Capital Mgmt Holdings Lc has invested 0.04% of its portfolio in Illumina, Inc. (NASDAQ:ILMN). Moreover, Rfg Advisory Group Limited has 0.24% invested in Illumina, Inc. (NASDAQ:ILMN) for 2,000 shares. Zevin Asset Management Limited Liability reported 18,430 shares or 0.72% of all its holdings. Opus Point Prtn Mngmt Limited Liability accumulated 18,741 shares or 2.54% of the stock. Thornburg Mngmt holds 0.11% or 101,931 shares in its portfolio. The Massachusetts-based De Burlo Gru has invested 0.84% in Illumina, Inc. (NASDAQ:ILMN). Employees Retirement Sys Of Texas, a Texas-based fund reported 5,000 shares. Friedberg Invest Mngmt last reported 7,950 shares in the company.
Insider Transactions: Since April 13, 2016, the stock had 0 insider purchases, and 30 insider sales for $18.12 million net activity. On Friday, August 12 the insider WHITFIELD ROY A sold $668,880. FLATLEY JAY T also sold $1.50M worth of Illumina, Inc. (NASDAQ:ILMN) shares. EPSTEIN ROBERT S had sold 300 shares worth $51,081 on Monday, August 22. Shares for $21,156 were sold by Dadswell Charles. Shares for $329,700 were sold by Bianchi Paul L on Monday, April 18. $376,835 worth of shares were sold by HENRY CHRISTIAN O on Monday, April 18. 5,000 shares were sold by EASTHAM KARIN, worth $726,750 on Wednesday, June 1.
More notable recent Illumina, Inc. (NASDAQ:ILMN) news were published by: Fool.com which released: “Why Illumina, Inc. Is Plunging Today” on October 11, 2016, also Investorplace.com with their article: “3 Stocks to Watch Tuesday: Illumina, Inc. (ILMN), Seagate Technology PLC (STX …” published on October 11, 2016, Investorplace.com published: “Why Alcoa Inc (AA), Illumina, Inc. (ILMN) and Seagate Technology PLC (STX) Are …” on October 11, 2016. More interesting news about Illumina, Inc. (NASDAQ:ILMN) were released by: Bloomberg.com and their article: “Illumina Dives as Quarterly Revenue Falls Short of Forecast” published on October 10, 2016 as well as Marketwatch.com‘s news article titled: “Illumina cuts Q3 revenue estimates, shares down 23%” with publication date: October 10, 2016.
ILMN Company Profile
Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array solutions for genetic analysis. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its clients in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. The Company’s BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has activities in the United States, Europe, Asia-Pacific and other markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.